Clinical Trial Update: A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial [Phase 1]

View source ↗

Summary

Phase 1 trial of a dendritic cell-based vaccine for multiple sclerosis has completed, reporting negative results in this first-in-human study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dendritic cell-based vaccine (experimental)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED